CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-10-08): Serum ribavirin level impacts outcome in HCV-HIV coinfection

Clinical

Serum ribavirin level impacts outcome in HCV-HIV coinfection

Last Updated: 2008-10-08 15:53:43 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The serum concentration of ribavirin influences the outcome of treatment of hepatitis C virus (HCV) genotype 1 or 4 infection in HIV-positive patients, results of a study indicate.

A ribavirin concentration of 2,300 ng/mL or less is a "strong predictor of nonresponse" in this patient population, the study team notes in the September issue of the Journal of Medical Virology.

Measuring serum ribavirin concentrations in these "difficult-to-treat patients could be used to optimize the ribavirin dose and so increase the probability of success," Dr. Florence Nicot from INSERM, Toulouse, France and colleagues conclude.

They investigated the relationship between serum ribavirin and pegylated interferon concentrations 3 and 6 months after the start of treatment, and treatment outcome in 35 HCV-HIV coinfected patients.

The serum levels of interferon were similar at 3 and 6 months, as were levels of ribavirin, although levels varied widely between patients.

Results showed no influence of the pegylated interferon concentration on treatment outcome, which is in keeping with a recent study, the authors note.

The ribavirin concentrations, on the other hand, tended to be higher in responders (2,322 ng/mL) than nonresponders (1,833 ng/mL). Moreover, responders infected with HCV genotype 1 or 4 had significantly higher ribavirin concentrations (2,672 ng/mL) than did similarly infected nonresponders (1,758 ng/mL).

"The ribavirin concentration could be important for predicting treatment outcome in patients infected with HIV and HCV genotype 1 or 4," Dr. Nicot and colleagues conclude.

In their study, a ribavirin concentration of 2,300 ng/mL was the best threshold for predicting a nonresponse in these patients, they note, adding that 86% of the patients with a concentration below this threshold were nonresponders.

J Med Virol 2008;80:1523-1529.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.